Absci Corporation (ABSI)
After hours:
| Previous Close | 4.4550 |
| Open | 4.5000 |
| Bid | 4.5200 x 200 |
| Ask | 4.5900 x 500 |
| Day's Range | 4.4700 - 4.6800 |
| 52 Week Range | 1.1110 - 6.7200 |
| Volume | |
| Avg. Volume | 1,559,863 |
| Market Cap | 517.92M |
| Beta (5Y Monthly) | 2.37 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Absci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024
VANCOUVER, Wash. and NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the first quarter before market open on Tuesday, May 14, 2024. Absci management will webcast a corresponding conference call beginning at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time to discuss its business developments, financial and operating resul
- GlobeNewswire
Absci to Participate in the 23rd Annual Needham Virtual Healthcare Conference
VANCOUVER, Wash. and NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming 23rd Annual Needham Virtual Healthcare Conference. Absci management is scheduled to present on Monday, April 8th at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time). Interested parties may access a live and archived webcast on the company’s investor relations website at: investors.ab
- GlobeNewswire
Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results
Initiated IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody Entered into collaboration with AstraZeneca for up to $247M in deal value, plus royalties Strengthened balance sheet raising approximately $86M in gross proceeds through underwritten common stock offering VANCOUVER, Wash. and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the f
